Lenalidomide Plus Hypomethylating Agent as a Treatment Option in Acute Myeloid Leukemia With Recurrent Genetic Abnormalities —AML With inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM
Acute myeloid leukemia with GATA2, MECOM has had a poor response to standard induction chemotherapy regimens. We retrospectively compared the data from patients who had received lenalidomide plus a hypomethylating agent with those who had received standard induction therapy. The overall response rate was greater for the patients who had received lenalidomide plus a hypomethylating agent compared with standard induction, suggesting a promising approach for patients with AML with GATA2, MECOM.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Lauren E. Merz, Anthony J. Perissinotti, Bernard L. Marini, Patrick W. Burke, Ashley Crouch, Harry P. Erba, Dale Bixby Tags: Original Study Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Chemotherapy | Genetics | Hematology | Leukemia | Lymphoma | Myeloma | Revlimid | Study